Portland, OR -- (SBWIRE) -- 09/25/2017 -- Cardiac biomarkers are protein-based traceable substances used as an indicator of biological state for diagnostic and prognostic purposes associated with cardiac conditions. Commercialization of highly advanced and accurate type of cardiac biomarkers has provided a novel platform for diagnosis of cardiac diseases. Continuous focus on pipeline research and developments from leading players and increased patient awareness across untapped regions such as India, China is largely driving the growth of cardiac biomarkers market.
Get sample Copy @ https://www.alliedmarketresearch.com/request-sample/309
The growing application of cardiac biomarkers as point of care (POC) testing facilitate quick results in chronic conditions, thus drives the market growth. However, specificity and sensitivity related concerns of single measurement cardiac biomarkers, premium pricing and certain government regulations would hinder the market growth. Also, the overall market growth would bank on novel progress made in cardiac treatments using multi-assay biomarkers. The life saving benefits of these multi-assay biomarkers would foster the revenue generation process as well as market penetration of novel cardiac biomarkers in the future..
Key findings of Cardiac Biomarkers Market:
Troponin segment is projected as a leading market segment throughout the forecast period
Revenue of myocardial infarction application segment is expected to grow almost threefold by 2020
Laboratory location of testing market segment still dominates the global market
Point of care location of testing segment is projected to grow at a CAGR of 22% during the forecast period
Countries like India and China holds prominent potential owing to higher count of undiagnosed cardiac patients
Browse Full report @ https://www.alliedmarketresearch.com/cardiac-biomarkers-market